Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae and persistent cough in children

Scandinavian Journal of Infectious Diseases

Volumn 31, Issue 3, 1999, Pages 281-286

  Hallander, Hans O ^a   Gnarpe, Judy ^b   Gnarpe, Håkan ^b   Olin, Patrick ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b GÄVLE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PERTUSSIS VACCINE;

ANTIBIOTIC THERAPY; ARTICLE; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; CHILDHOOD DISEASE; CHLAMYDOPHILA PNEUMONIAE; COMORBIDITY; COUGHING; DISEASE DURATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIAE; PERTUSSIS; PRESCHOOL CHILD;

ANTIBODIES, BACTERIAL; BORDETELLA; BORDETELLA INFECTIONS; BORDETELLA PERTUSSIS; CHILD, PRESCHOOL; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; COUGH; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HUMANS; INFANT; MALE; MYCOPLASMA INFECTIONS; MYCOPLASMA PNEUMONIAE; NASOPHARYNX; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; WHOOPING COUGH;

EID: 0032784457     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365549950163581     Document Type: Article

References (27)

1. Isacson J, Trollfors B, Taranger J, Zackrisson G, Lagergård T. How common is whooping cough in a nonvaccinating country? Pediatr Infect Dis J 1993; 12: 284-8.
2. Heininger U, Klemens S, Schmitt-Grohe S, Lorenz C, Rost R, Christenson P, et al. Clinical characteristics of Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 1994; 13: 306-9.
3. Mastrantonio P, Stefanelli P, Giuliano M, Herrera Rojas Y, Ciofi degli Atti M, et al. Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. J Clin Microbiol 1998; 36: 999-1002.
4. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular and a whole-cell pertussis vaccine. N Engl J Med 1996; 334: 349-55.
5. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. Efficacy trial of acellular pertussis vaccine. Technical Report, Trial I. SMI-tryck 1995; 105: 1-70.
6. Saikku P. Atypical respiratory pathogens. Clin Microbiol Infect 1997; 3: 599-604.
7. McGregor K, Chang BJ, Mee BJ, Riley TV. Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases. Eur J Clin Microbiol Infect Dis 1998; 17: 219-34.
8. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin Infect Dis 1993; 17 (Suppl 1): S37-46.
9. Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. Erythromycin ethylsuccinate. Pediatr Infect Dis 1995; 14: 471-7.
10. Hallander HO, Reizenstein E, Renemar B, Rasmuson G, Mardin L, Olin P. Comparison of nasopharyngeal aspirates with swabs for culture of Bordetella pertussis. J Clin Microbiol 1993; 31: 50-2.
11. Regan J and Lowe F. Enrichment medium for the isolation of Bordetella. J Clin Microbiol 1977; 6: 303-9.
12. Reizenstein E, Hallander HO, Blackwelder WC, Kuhn I, Ljungman M, Möllby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 1995; 183: 279-90.
13. Gnarpe J, Eriksson K. Sample preparation for Chlamydia pneumoniae PCR. APMIS 1995; 103: 307-8.
14. Tong CYW, Sillis M. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993; 46: 313-7.
15. Bernet C, Garret M, de Barbeyrac B, Bebear C, Bonnet J. Detection of Mycoplasma pneumoniae by using the polymerase chain reaction. J Clin Microbiol 1989; 27: 2492-6.
16. von König CHW, Rott H. Bogaerts H, Schmitt HJ. A serological study of organisms possbly associated with pertussis-like coughing. Pediatr Infect Dis J 1998; 17: 645-9.
17. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997; 350: 1569-77.
18. Lund-Olsen I, Lundbäck A, Gnarpe J, Gnarpe H. Prevalence of specific antibodies to Chlamydia pneumoniae in children with acute respiratory infections. Acta Pediatr 1994; 83: 1143-5.
19. Grayston JT. Chlamydia pneumoniae (TWAR) infections in children. Pediatr Inf Dis J 1994; 13: 675-5.
20. Normann E, Gnarpe J, Gnarpe H, Wettergren B. Chlamydia pneumoniae in children with acute respiratory tract infections. Acta Paediatr 1998; 87: 23-7.
21. Normann E, Gnarpe J, Gnarpe H, Wettergren B. Chlamydia pneumoniae in children attending day-care centers in Gävle, Sweden. Pediatr Infect Dis J 1998; 17: 474-8.
22. Falck G, Gnarpe J, Gnarpe H. Prevalence of Chlamydia pneumoniae in healthy children and in children with respiratory tract infections. Pediatr Infect Dis J 1997; 16: 549-54.
23. Gnarpe J, Gnarpe H, Sundelöf B. Endemic prevalence of Chlamydia pneumoniae in subjectively healthy persons. Scand J Infect Dis 1991; 23: 387-8.
24. Gnarpe J, Lundbäck A, Sundelöf B, Gnarpe H. Prevalence of Mycoplasma pneumoniae in subjectively healthy individuals. Scand J Infect Dis 1992; 24: 161-4.
25. WHO meeting on case definition of pertussis: Geneva, 10-11 January 1991. Geneva: World Health Organization, 1991: 4-5 (Issue no. MIN/EPI PERT/91.1.
26. Stehr K, Cherry JD, Heininger U, Schmitt-Grohe' S, Uberall M, Laussucq S, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DtaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101: 1-11.
27. Trollfors B, Taranger J, Lagergård T. A placebo-controlled trial of a pertussis-toxoid vaccine N Engl J Med 1995; 333: 1045-50.